AN2 Therapeutics is a biopharmaceutical company developing medicines for serious diseases with significant unmet treatment needs. Its work centers on a boron chemistry platform, which uses the distinctive properties of boron to explore new therapeutic possibilities and develop potential boron-based treatments. The company aims to address critical gaps in care, advancing therapies for infectious diseases and cancer.

AN2 reports three clinical-stage programs and highlights research in polycythemia vera, Chagas disease, Mycobacterium abscessus infection, and oncology programs targeting PI3K and ENPP1. Its activities include discovering and developing potential medicines, conducting clinical trials, and sharing scientific findings through presentations and publications. The company also provides investor information and updates on research collaborations and program progress.

Based in Menlo Park, California, AN2 Therapeutics has a team focused on changing the course of disease and making an impact worldwide. Through its boron-based science and development pipeline, the company seeks to unlock new therapeutic options for patients and address important needs across its areas of research.